A single dose of an FDA-approved intravenous nutrition source may significantly reduce the toxicity and increase the bioavailability of platinum-based cancer drugs, according to a study published in Scientific Reports (2015; doi:10.1038/srep10881).
Platinum-based drugs, including cisplatin, carboplatin, and oxyplatin, have been used to treat cancer for more than 35 years. While they remain among the most prescribed and most potent chemotherapy drugs, they also cause serious side effects including kidney damage.
Many of the side effects of these drugs occur when the drug settles in healthy tissue. To deliver these drugs in a more targeted way, researchers have created nanoscale delivery systems engineered to make the drug reach and accumulate at the tumor site. However, tests of these nanodrugs show that only between one and 10% of the drugs are delivered to the tumor site, with the majority of the remainder being diverted to the liver and spleen.
“The body’s immune system, especially the liver and spleen, has been one of the biggest stumbling blocks in developing nanoscale chemotherapy drug delivery systems,” said Chien Ho, PhD, of Carnegie Mellon University in Pittsburgh, Pennsylvania. “When the drugs collect in those organs, they become less available to treat the cancer, and can also cause toxicity.”
In the past few years, Ho and his colleagues were developing cellular nanotags to help detect organ rejection, when Ho noticed that Intralipid, a fat emulsion FDA-approved for use as an intravenous nutrition source, reduced the amount of nanoparticles that were being cleared by the liver and spleen by approximately 50%. As a result, the nanoparticles remained in the blood stream for longer periods of time.
Ho and his colleagues decided to see if Intralipid had the same effect on platinum-based anticancer nanodrugs. In the newly published study, the researchers administered a single, clinical dose of Intralipid to a rat model. One hour later, they administered a dose of a platinum-based chemotherapy drug that had been incorporated into a nanoparticle.
Twenty-four hours after the drug was administered, the researchers found that pre-treatment with Intralipid reduced the accumulation of the platinum-based drug by 20.4% in the liver, 42.5% in the spleen, and 31.2% in the kidney. Consequently, in these organs, the toxic side effects of the nanodrug decreased significantly.
Furthermore, the researchers found that Intralipid pretreatment allowed more of the drug to remain available and active in the body for longer periods of time. After 5 hours, availability of the drug was increased by 18.7%, and after 24 hours, it was increased by 9.4%. The researchers believe that this increased availability will allow more of the drug to reach the tumor site, and could perhaps also allow clinicians to reduce the dosage needed to treat a patient.
The researchers are currently investigating the possibility of bringing this research to a clinical trial.